At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 96 enrolled
Drug / intervention
Xenetix-CT perfusion imagingdrug
Likely dose
Xenetix-CT perfusion imaging 50 mlfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Diagnostic Contribution of XENETIX® CT PERFUSION in Pre-therapeutical Assessment of Hepatocellular Carcinoma
In Brief
A Phase 4 clinical trial evaluating Xenetix-CT perfusion imaging for Hepatocellular Carcinoma. Completed, enrolled 96 participants across 5 sites in 4 countries.
Detailed Summary
The purpose of this study is to prospectively determine the diagnostic value of Xenetix-CT perfusion for the discrimination between well-differentiated hepatocellular carcinomas (HCC) and poorly/moderately differentiated HCC, in histo-pathologically proven HCC, and with the aim to cover the entire liver.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHepatocellular Carcinoma
CountriesAustria, Germany, South Korea, Switzerland
Collaborators--
Timeline
Phase 4CompletedFinished
201220132014201520162017201820192020202120222023202420252026
Enrollment StartApr 2012
First PostedJul 2012
Primary CompletionOct 2014
TodayJul 2026
First PostedJul 13, 2012
Enrollment StartApr 1, 2012
Primary CompletionOct 1, 2014
TodayJul 2, 2026
Enrollment to primary: 2.5 yearsPosted 14.0 years ago
Interventions
Xenetix-CT perfusion imagingdrug
Injection of 50 ml of Xenetix